Cytostatic extravasation: a modern view on prevention, management and staff education

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Cytostatic extravasation is a rare but severe complication of chemotherapy administration. This article reviews current prevention and treatment strategies according to international (ESMO, MASCC, NCCN) and Russian recommendations. The mechanisms of tissue injury are discussed for different drug classes, including anthracyclines, vinca alkaloids, taxanes, and platinum agents. A step-by-step algorithm and detailed table of antidotes (dexrazoxane, hyaluronidase, sodium thiosulfate, DMSO) are presented. The article highlights practical implementation issues in Russian clinics, where lack of standardized extravasation kits and antidotes remains a problem. Early recognition, staff training, and safety culture are key to reducing complications.

 

About the authors

Elena F. Satirova

"Our Time" Clinic

Author for correspondence.
Email: lena.satirova@mail.ru
Russian Federation, 103 Leninsky Prospekt, Moscow 119421

References

  1. Pérez Fidalgo J.A., García Fabregat L., Cervantes A. et al. ESMO Guidelines Working Group. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. Ann Oncol 2012;23(Suppl 7):167–73. doi: 10.1093/annonc/mds294
  2. Mouridsen H.T., Langer S.W., Buter J. et al. Treatment of anthracycline extravasation with Savene (dexrazoxane): results from two prospective clinical multicentre studies. Ann Oncol 2007;18(3):546–50. doi: 10.1093/annonc/mdl413
  3. Schulmeister L. Extravasation management: clinical update. Semin Oncol Nurs 2011;27(1):82–90. doi: 10.1016/j.soncn.2010.11.010
  4. Bertelli G., Gozza A., Forno G.B. et al. Topical dimethylsulfoxide for the prevention of soft tissue injury after extravasation of vesicant cytotoxic drugs: a prospective clinical study. J Clin Oncol 1995;13(11):2851–5. doi: 10.1200/JCO.1995.13.11.2851
  5. Kreidieh F.Y., Moukadem H.A., El Saghir N.S. Overview, prevention and management of chemotherapy extravasation. World J Clin Oncol 2016;7(1):87–97. doi: 10.5306/wjco.v7.i1.87
  6. Kimmel J., Fleming P., Cuellar S. et al. Pharmacological management of anticancer agent extravasation: a single institutional guideline. J Oncol Pharm Pract 2018;24(2):129–38. doi: 10.1177/1078155217690924
  7. Sauerland C., Engelking C., Wickham R., Corbi D. Vesicant extravasation part I: Mechanisms, pathogenesis, and nursing care to reduce risk. Oncol Nurs Forum 2006;33(6):1134–41. doi: 10.1188/06.ONF.1134-1141
  8. Matsumoto K., Ryushima Y., Sato J. et al. Extravasation associated with cancer drug therapy: multidisciplinary guideline of the Japanese Society of Cancer Nursing, Japanese Society of Medical Oncology, and Japanese Society of Pharmaceutical Oncology. ESMO Open.2024;9(10):103932. doi: 10.1016/j.esmoop.2024.103932
  9. Thomas T., Clark C., Backler C. et al. ONS/ASCO Guideline on the management of antineoplastic extravasation. Clin J Oncol Nurs 2025;29(5):384–99. doi: 10.1188/25.CJON.384-399
  10. Langer S.W. Dexrazoxane for the treatment of chemotherapy-related side effects. Cancer Manag Res 2014;6:357–63. doi: 10.2147/CMAR.S47238
  11. Pérez-Fidalgo J.A., Cervantes A. Comment on: management of chemotherapy extravasation: ESMO-EONS Clinical practice guidelines. Ann Oncol 2013;24(4):1129–30. doi: 10.1093/annonc/mdt024
  12. Kane R.C., McGuinn W.D. Jr, Dagher R. et al. Dexrazoxane (Totect): FDA review and approval for the treatment of accidental extravasation following intravenous anthracycline chemotherapy. Oncologist 2008;13(4):445–50. doi: 10.1634/theoncologist.2007-0247
  13. Conde-Estévez D., Mateu-de Antonio J. Treatment of anthracycline extravasations using dexrazoxane. Clin Transl Oncol 2014;16(1):11–7. doi: 10.1007/s12094-013-1100-7
  14. Pericay C., López A., Soler J.R. et al. Extravasation of oxaliplatin: an infrequent and irritant toxicity. Clin Transl Oncol 2009;11(2):114–6. doi: 10.1007/s12094-009-0324-z
  15. Buidenok Yu.V., Obukhova O.A. Practical recommendations for the prevention and treatment of the effects of extravasation of antitumor drugs. Malignant tumors: Practical recommendations RUSSCO. 2024. Vol. 14, No. 3s2. Available by: https://www.rosoncoweb.ru/standarts/RUSSCO/ 2024/2024-2-13.pdf
  16. European Oncology Nursing Society (EONS). Extravasation Guidelines 2007. EONS, Brussels. Eur J Oncol Nurs 2008;12(4):357–61. doi: 10.1016/j.ejon.2008.07.003
  17. Буйденок Ю. В. Рекомендации по профилактике и лечению последствий экстравазации противоопухолевых препаратов. Злокачественные опухоли: Практические рекомендации RUSSCO 2024;(14):171–81. doi: 10.18027/2224-5057-2024-14-3s2-171-181

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2026 ABV-Press

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.
СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-86325 от  11.12.2023.